A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

MP-101 will be evaluated in this study to see if it is safe and tolerable.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Proof of Concept Study in Patients With Short Bowel Syndrome

NCT04379856

Short Bowel Syndrome

UNKNOWN PHASE1/PHASE2

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

NCT04881825

Short Bowel Syndrome

ENROLLING_BY_INVITATION PHASE3

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

NCT04991311

Short Bowel Syndrome

COMPLETED PHASE3

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

NCT03882918

Angelman Syndrome

TERMINATED PHASE3

Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)

NCT02324049

Mucopolysaccharidosis IIIB

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Short Bowel Syndrome Short Gut Syndrome SBS Short Gut

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Subjects

Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

Group Type EXPERIMENTAL

0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

Intervention Type DRUG

0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be male or female adults, 18 years of age or older
* Have SBS that is inadequately controlled on current antidiarrheal medication (e.g., loperamide or diphenoxylate), including subjects with ileostomies
* Must have been deemed a completer of study protocol MP-101-CL-001.
* Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months of natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy)
* Females of childbearing potential must agree to use 1 of the following acceptable birth control methods:

* Surgically sterile (hysterectomy or bilateral oophorectomy)
* Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation)
* Intrauterine device (IUD) in place for at least 3 months
* Abstinence (not having sexual intercourse)
* Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion
* Stable hormonal contraceptive for at least 3 months prior to study and through study completion
* Vasectomized partner
* Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at Visit 1.
* Be able to understand and provide signed informed consent

Exclusion Criteria

* Have any history of or active neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic disease that is considered clinically significant, is not currently controlled by medication, and is stable as deemed by the Investigator
* Are currently taking antibiotics for bacterial overgrowth
* Have known or suspected pregnancy, planned pregnancy, or lactation
* Have a planned surgery during the course of the study
* Have a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No